Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1345155 | 0.86 | DPP7 (0.40) | ALOX15 | |
| SCHEMBL1345597 | 0.85 | DPP7 (0.42) | ALDH1A1ALOX15 | |
| SCHEMBL1769490 | 0.85 | HTT (0.53) | SMN1; SMN2ALDH1A1GAATSHRKDM4E | |
| SCHEMBL1769493 | 0.85 | HTT (0.53) | SMN1; SMN2ALDH1A1GAATSHRKDM4E | |
| SCHEMBL1768813 | 0.80 | HTT (0.48) | SMN1; SMN2ALDH1A1LMNAHTTHSD17B10 | |
| SCHEMBL1768811 | 0.80 | HTT (0.48) | SMN1; SMN2ALDH1A1LMNAHTTHSD17B10 | |
| SCHEMBL13585349 | 0.79 | TAAR1 (0.51) | SMN1; SMN2ALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL13585347 | 0.79 | TAAR1 (0.51) | SMN1; SMN2ALDH1A1TSHRLMNAHSD17B10 | |
| SCHEMBL1768474 | 0.78 | TSHR (0.52) | SMN1; SMN2ALDH1A1GAATSHRKDM4E | |
| SCHEMBL1768478 | 0.78 | TSHR (0.52) | SMN1; SMN2ALDH1A1GAATSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828109-B1 | GUANIDINE DERIVATIVES AS INHIBITORS OF DDAH | UCL BUSINESS PLC (GB) | 2013-06-05 | — | — | EP | disclosed |
| US-8063104-B2 | Guanidine derivatives as inhibitors of DDAH | UCL BUSINESS PLC (GB) | 2011-11-22 | — | — | US | disclosed |
| US-20090069331-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF DDAH | UCL Biomedica PLC c/o Finance Division University College of London (GB) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069331-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF DDAH | DDAH1, DOHH, IMPDH1 | SMN1; SMN2 1730/4885ALDH1A1 123/4885GAA 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.